- Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
- Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
- Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
- Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
- Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
More ▼
Key statistics
On Friday, Rocket Pharmaceuticals Inc (RCKT:NMQ) closed at 21.32, 43.18% above the 52 week low of 14.89 set on Aug 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.55 |
---|---|
High | 22.10 |
Low | 20.95 |
Bid | 20.75 |
Offer | 22.05 |
Previous close | 21.45 |
Average volume | 681.87k |
---|---|
Shares outstanding | 90.78m |
Free float | 85.86m |
P/E (TTM) | -- |
Market cap | 1.94bn USD |
EPS (TTM) | -2.87 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼